Carter Cameron S, Barch Deanna M
University of California at Davis, USA.
Schizophr Bull. 2007 Sep;33(5):1131-7. doi: 10.1093/schbul/sbm081. Epub 2007 Jul 14.
The goal of this article is to discuss ways to further improve the search for potentially procognitive agents that could be used to enhance cognition and functional outcome in schizophrenia. In particular, we focus on the potential advantages to this process of using a contemporary, cognitive neuroscience-based approach to measuring cognitive function in clinical trials of procognitive agents in schizophrenia. These tools include computer-administered tasks that measure specific cognitive systems (such as attention, working memory, long-term memory, cognitive control) as well as the component cognitive processes that comprise these more overarching systems. The advantages of using these tools include the ability to identify and use homologous animal and human models in the drug discovery and testing process and the ability to incorporate noninvasive functional imaging measures into clinical trial contexts at several different phases of the drug development process. However, despite the clear potential advantages to using such methods, a number of barriers exist to their translation from basic science tools to tools for drug discovery. We discuss the development and implementation of a new project, Cognitive Neuroscience Treatment to Improve Cognition in Schizophrenia, designed to identify and overcome these barriers to the translation of cognitive neuroscience measures and methods into regular use in the drug discovery and development process of cognition-enhancing agents for use in schizophrenia.
本文的目的是讨论如何进一步改进寻找潜在促认知药物的方法，这些药物可用于改善精神分裂症患者的认知和功能结局。特别是，我们重点关注在精神分裂症促认知药物临床试验中，采用基于当代认知神经科学的方法来测量认知功能，这一过程的潜在优势。这些工具包括计算机辅助任务，用于测量特定的认知系统（如注意力、工作记忆、长期记忆、认知控制）以及构成这些更宏观系统的认知过程组成部分。使用这些工具的优势包括在药物发现和测试过程中能够识别和使用同源的动物和人类模型，以及在药物开发过程的几个不同阶段将非侵入性功能成像测量纳入临床试验环境的能力。然而，尽管使用此类方法具有明显的潜在优势，但将其从基础科学工具转化为药物发现工具仍存在一些障碍。我们讨论了一个新项目“改善精神分裂症认知的认知神经科学治疗”的开发和实施情况，该项目旨在识别并克服这些障碍，以便将认知神经科学测量方法转化为常规方法，用于精神分裂症认知增强药物的药物发现和开发过程。
